18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy

NCT03741231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2019-05-06

No results posted yet for this study

Summary

Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.

Conditions

  • Melanoma
  • NSCLC
  • Positron-Emission Tomography
  • Immunotherapy
  • 18F-FDG

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741231 on ClinicalTrials.gov